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Treatment of polycystic kidney disease with a novel tyrosine (ADPKD) and autosomal recessive PKD (ARPKD).
kinase inhibitor. ADPKD is characterized by renal cyst formation and
Background. We have previously demonstrated an essential extrarenal manifestations, including hepatic and pancre-role for increased epidermal growth factor receptor (EGFR)
atic cysts, cerebral aneurysms, and an increased inci-activity in mediating renal cyst formation and biliary epithelial
dence of diverticulosis and valvular heart abnormalitieshyperplasia in murine models of autosomal recessive polycystic
kidney disease (ARPKD). This study was designed to deter- [1]. ADPKD is caused by mutations in at least three
mine whether or not treatment with a newly developed inhibi- different genes [2–4]. An investigation into the normal
tor of EGFR tyrosine kinase activity (EKI-785) would reduce distribution and functions of the proteins encoded byrenal and biliary abnormalities in murine ARPKD.
these genes, as well as their role in cystogenesis, is under-Methods. Balb/c-bpk/bpk (BPK) litters were treated with
way. ARPKD is invariably characterized by the forma-EKI-785, an EGFR-specific tyrosine kinase inhibitor. Animals
were treated by intraperitoneal injection beginning at postnatal tion and enlargement of renal collecting tubule (CT)
day 7 and were treated until postnatal day 24 or 48. EKI-785’s cysts as well as biliary ectasia and fibrosis. Despite the
effectiveness was measured by a reduction in the renal cystic
wide clinical spectrum of ARPKD, linkage analysis stud-index, an increased life span, and maintenance of normal renal
ies suggest that ARPKD is due to mutations in a singlefunction.
Results. Treatment of BPK mice with EKI-785 resulted in gene localized to a 3.8 centiMorgan (cM) interval on
a marked reduction of collecting tubule (CT) cystic lesions, chromosome 6p21-p12 [5, 6].
improved renal function, decreased biliary epithelial abnormal- A variety of animal models as well as in vitro cell
ities, and an increased life span. Untreated cystic animals died
culture systems using human and animal kidney cells hasof renal failure at postnatal day 24 (P-24) with a CT cystic
been used to investigate mechanisms of cystogenesis.index of 4.8, a maximal urine osmolarity of 361 mOsm, and
moderate to severe biliary abnormalities. Cystic animals These studies have reported abnormalities in epithelial
treated with EKI-785 to postnatal day 48 (P-48) were alive and cell growth, fluid secretion, and extracellular matrix com-
well with normal renal function, a reduced CT cystic index position [7]. Evidence from a number of laboratoriesof 2.0 (P , 0.02), a threefold increased in maximum urinary
demonstrates a significant role for the epidermal growthconcentrating ability (P , 0.01), and a significant decrease in
factor (EGF)/transforming growth factor-a (TGF-a)/biliary epithelial proliferation/fibrosis (P , 0.01).
Conclusion. This study demonstrates that EKI-785 has ther- EGF receptor (EGFR) axis in promoting epithelial hy-
apeutic effectiveness in improving histopathologic abnormali- perplasia, with resultant renal cyst formation and en-
ties and decreasing mortality in murine ARPKD. largement in murine and human ADPKD and ARPKD
[8–22]. In addition, in the Balb/c-bpk/bpk (BPK) model
of ARPKD, we have suggested that similar abnormalities
Polycystic kidney disease (PKD) encompasses two ge-
of EGFR expression may mediate biliary epithelial hy-netically distinct conditions: autosomal dominant PKD
perplasia and ductal ectasia [13, 14].
We have previously demonstrated an essential role
1 See Editorial by Grantham, p. 339 for EGFR activity in promoting renal cyst formation
through genetic manipulation [18]. The waved-2 (wa-2)Key words: epidermal growth factor receptor, autosomal recessive
PKD, bpk mice, biliary epithelial ectasia, collecting tubule cysts. mutation produces a single amino acid change in the
EGFR and results in decreased tyrosine kinase activityReceived for publication May 13, 1999
of the EGFR [23]. Crossing this hypomorphic EGFRand in revised form August 15, 1999
Accepted for publication August 20, 1999 allele (waved-2) into cystic mice carrying the recessive
orpk (Oak Ridge polycystic kidneys) mouse mutation 2000 by the International Society of Nephrology
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[24] reduced the activity of the EGFR in affected animals tic animals BPK/BPK, heterozygotes BPK/1, and wild-
type 1/1 normals) were injected intraperitoneally (IP)[18]. Animals homozygous for both mutant genes (orpk
and wa-2) demonstrated a marked reduction in CT cyst with 25, 50, 60, 80, 90, and 100 mg/kg of EKI-785 every
three days. These dosages were based on previous phar-formation and improved CT function that was directly
correlated with reduced tyrosine kinase activity in the macologic studies of the compound in other mouse
strains [25]. Morphologic analysis was performed to de-double mutants [18].
The purpose of this study was to determine whether termine reduction of renal cystic lesions as well as BDE
and evaluation of renal and extrarenal organ toxicity.in vivo pharmacologic inhibition of the EGFR tyrosine
kinase activity would be effective in: (a) reducing the Animals were treated from P-7 to P-22 (6 doses), and
kidney, liver, heart, spleen, stomach, and thymus tissuesdevelopment and enlargement of CT cysts, (b) improving
renal function, (c) decreasing biliary epithelial abnormal- were harvested at P-24. A minimum of 6 affected animals
and 12 unaffected animals were analyzed at each dosage.ities, and (d) decreasing mortality in murine ARPKD.
In these studies, a novel, EGFR specific, tyrosine kinase Control animals for these studies included EKI-785–
treated and 2untreated (vehicle only) littermates. Theinhibitor (TKI), which has potent effects in retarding in
vitro cyst formation [21], was used to treat control and vehicle used for IP injections was 0.2% Klucell (hydroxy-
propylcellulose) in saline.BPK cystic mice [13, 14]. Pharmacologic inhibition of
EGFR tyrosine kinase activity in vivo resulted in a
Survival studiesmarked reduction in the number and size of CT cystic
lesions, improved renal tubular function, reduced biliary The average life span of BPK cystic mice is 24 days
[14]. To determine whether EKI-785 treatment signifi-ductule ectasia, and an increased life span in treated
animals. cantly prolonged life, 51 animals (16 cystic and 44 unaf-
fected) were treated with EKI-785 at 90 mg/kg every
three days from P-7 to P-46 or until death. The dosage
METHODS
of 90 mg/kg was determined as optimal from the dose-
Epidermal growth factor receptor tyrosine response studies (discussed later in this article). In addi-
kinase inhibition tion, eight unaffected animals were sham injected with
vehicle only. At day 48, water was withdrawn from allTyrosine kinase inhibition was accomplished with
EKI-785, a TKI specific for EGF and Erb/B2 receptors surviving animals, with the exception of four affected
animals. After eight hours of water deprivation, urine[25]. This compound covalently binds to EGFR, inhibits
kinase activity of the protein (IC50 5 370 6 120 and blood samples were collected for renal function and
tubular function determination, and kidney and liverpmol/L), blocks EGF-stimulated autophosphorylation of
the receptor (IC50 5 5 nmol/L), inhibits cell prolifera- tissues were harvested for morphometric analysis. To
determine the effect of drug withdrawal, EKI-785 treat-tion, and blocks the growth of tumors that overexpress
EGFR [25]. The duration of EKI-785 activity is depen- ment was stopped in the four surviving affected animals,
and these animals were closely monitored until theydent on the half-life of the compound as well as the
turnover rate of EKI-785–bound EGFR in the plasma demonstrated premorbid behavior such as listlessness,
especially when touched, and head drooping. The ani-membrane. Preliminary time course experiments dem-
onstrated that administration of EKI-785 every three mals were then sacrificed, and kidney and liver tissues
were harvested for morphometric analysis.days resulted in optimal inhibition with minimal toxicity.
Balb/c-bpk/bpk model Histology, immunohistology, and determination of
segmental nephron cyst localizationThe BPK model, a murine model of ARPKD, arose
as a spontaneous mutation in an inbred colony of Balb/c All kidney and liver tissues were fixed in 4.0% para-
formaldehyde in phosphate buffer (pH 7.4) for 30 min-mice. Homozygous BPK mice develop massively en-
larged kidneys and die of renal failure at an average utes at 48C. Tissues were then washed, dehydrated
through graded acetone, and embedded in Immunobedepostnatal age of 24 days (P-24) [13, 14]. The average age
of death of untreated affected animals is 24 days with a plastic embedding medium (Polysciences, Warrington,
PA, USA). Sections were cut at 4 mmol/L on an ultrami-range of 21 to 29 days. Extrarenal manifestations include
biliary proliferation and ductal ectasia (BDE). Because crotome, mounted on glass slides, and stained with hema-
toxylin (all tissues) or segment-specific lectins (kidneyof the recessive nature of this disease, wild-type 1/1
and heterozygous bpk/1 mice are phenotypically normal. only). Segmental nephron cystic localization and the CT
cystic index were quantitated in each experimental group
Dose-response studies by combining morphometric analysis with light micros-
copy and immunohistologic techniques [17–19, 22, 26].Beginning at postnatal day 7 (P-7), entire litters from
proven BPK heterozygous breeders (including BPK cys- Cyst localization was studied by segment-specific lectin
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binding using Dolichos biflorus agglutinin (DBA) as a
marker for CTs and Lotus tetragonolobus (LTA) as a
marker for proximal tubules [14, 16–19, 22, 27].
The immunostaining procedure used was our pre-
viously described post-embedded staining technique spe-
cifically developed for localization of antigens and lectins
in plastic sections [28]. Sections 4 mmol/L thick were
etched, trypsinized, and incubated overnight at 48C with
biotinylated lectins (3.57 mg/mL for LTA and 6.25
mg/mL for DBA), followed by incubation with extravi-
den peroxidase (1/400) for 90 minutes at room tempera-
ture. Sections were then stained with 0.05% diaminoben-
zidine and 0.01% hydrogen peroxide for 10 minutes and
were counter stained with hematoxylin.
Renal cystic index
The degree of tubular cyst formation was quantitated
by use of a cystic index. The index was derived from
basic light microscopic morphometric methods [26] and Fig. 1. Dose-response curve of EKI-785. Drug delivered by IP injection
every three days starting at postnatal day 7 (P-7) and continuing tohas been standardized to quantitate cyst formation in
P-22 with tissue harvested at P-24 (6 total doses). The number of animalsvivo and in vitro [14, 16–19, 22]. Following routine histo-
treated/analyzed at each dose was 6 at 25 mg/kg, 8 at 50 mg/kg, 14 at
logic preparation, 10 to 12 evenly spaced 4 mmol/L thick 60 mg/kg, 8 at 80 mg/kg, 14 at 90 mg/kg, and 8 at 100 mg/kg. Data
demonstrate that increased concentrations of EKI-785 result in dose-sections of kidney were graded for cyst formation in CT
dependent reductions in collecting tubule (CT) cystic index (s), as welltubular segments (Dolichous Biflorus positive) on a scale
as dose-dependent reductions in biliary proliferation and ductule ectasia
of 0 (no observable cysts) through 5 (multiple cysts larger (BDE; r).
than 0.20 mm) [22]. For each treatment group, a CT
cystic index was determined on a total of at least six
affected pups.
an automated clinical chemistry analyzer by the Seelig
Hepatic biliary ductal ectasia and proliferation modification of the Jaffe method [30].
Following routine histologic preparation, eight evenly
Statistical analysisspaced (at least 32 mmol/L apart), 4 mmol/L thick, hema-
The significance of differences between experimentaltoxylin stained liver sections were graded (0 through 4)
groups was determined by a one-way analysis of variancefor biliary ductal ectasia and biliary epithelial prolifera-
[31]. Results are expressed as mean 6 sd.tion using the following scale: 0, all portal triads have
normal biliary ductal profiles; 1, #15% of portal triads
have ectactic biliary ducts and biliary epithelial hyperpla- RESULTS
sia; 2, .15% but #30% of portal triads have ectactic
Dose-response studiesbiliary ducts and biliary epithelial hyperplasia; 3, .30%
Both cystic and noncystic control animals were in-but #50% of portal triads have ectactic biliary ducts and
jected IP with varying doses of EKI-785 (25, 50, 60, 80,biliary epithelial hyperplasia; 4, .50% of portal triads
90, and 100 mg/kg) every three days starting at P-7.have ectactic biliary ducts and biliary epithelial hyper-
Kidney and liver tissues were harvested at P-24, and aplasia.
CT cystic index and hepatic biliary ductule ectasia index
Analysis of renal function and maximal urinary were determined for each dose. Figure 1 demonstrates
concentrating ability that increased doses of EKI-785 resulted in a decreased
CT cystic index. Treatment of cystic animals with 25Animals were deprived of water for eight hours prior
mg/kg resulted in an average CT cystic index of 4.3,to the collection of urine samples for urine osmolarity
which was minimally reduced compared with the 4.8 CTmeasurements. Blood samples were obtained by cardiac
index of untreated cystic animals. Increasing the dose topuncture for serum blood urea nitrogen (BUN) and cre-
50 mg/kg resulted in a CT cystic index of 3.6, a notableatinine measurements. Serum BUN was quantitatively
decrease in CT cystic lesions compared with untreateddetermined on an automated clinical chemistry analyzer
cystic animals. Treatment with 90 mg/kg every three daysusing the Boehringer Mannheim urease-triggered meth-
resulted in a striking reduction in both size and numberodology based on the method of Talke and Schubert
[29]. Serum creatinine was quantitative determined on of CT cystic lesions (Fig. 1 and Fig. 2C) compared with
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untreated controls (Fig. 1 and Fig. 2A) The 90 mg/kg murine models of ARPKD (cpk [32], orpk [24]), cystic
dosage reduced the CT cystic index to 1.6 (P , 0.02), lesions first appear in the proximal tubules. As the dis-
without morphologic evidence of renal or extrarenal tox- ease progresses, the site of cystic lesions shifts to the CT.
icity. Untreated BPK mice have an equal ratio of PT to CT
Treatment of unaffected mice with EKI-785 from P-7 cysts at day 10. The majority of cysts (85 to 90%) in
to P-24 (90 mg/kg every 3 days) resulted in a 10% de- affected mice at the time of death are localized to the
crease in total body weight and an 8% decrease in kidney CT. In EKI-785–treated BPK cystic mice, the ratio of
weight compared with untreated controls. The kidney PT to CT cysts is approximately one at P-46.
weight to body weight ratio of unaffected animals re- Treatment with 90 mg/kg of EKI-785 resulted in a
mained unchanged at 1.2%. However, treatment of cystic significantly (P , 0.02) reduced BDE index value of
animals with EKI-785 resulted in a drastically reduced 1.6 (Table 1 and Fig. 2F) compared with the untreated
kidney weight to body weight ratio from 20% in un- control BDE index value of 3.2. (Table 1 and Fig. 2B).
treated cystic mice to 4.4% in EKI-785–treated cystic Four animals were treated EKI-785 (90 mg/kg, IP ev-
mice (body weight reduced 5%, kidney weight reduced ery 3 days) from P-7 until P-46 at which time the drug
80%). This reduction in kidney weight to body weight was withdrawn. Figure 3 demonstrates that following
ratio of cystic EKI-785–treated animals demonstrates drug withdrawal, the slope and time course of the CT
that the reduced kidney size is not due to nonspecific, cyst formation and enlargement are similar to that of
global effects on growth. untreated, affected BPK animals. Within 18 days of EKI-
This dosage was thus used for all additional studies. 785 withdrawal, all cystic animals had died of renal fail-
Figure 1 also demonstrates that increasing the EKI-785 ure with massively enlarged kidneys.
dosage resulted in a dose-dependent reduction in biliary
ductal ectasia and biliary epithelial proliferation. Treat- Analysis of renal function and maximal urinary
ment with 90 mg/kg of EKI-785 resulted in a significantly concentrating ability
(P , 0.02) decreased BDE index value of 1.2 (Fig. 1
The data in Table 1 demonstrate that EKI-785 (90and Fig. 2D) compared with the untreated control BDE
mg/kg) treatment of cystic mice maintained kidney func-index value of 3.2. (Fig. 1 and Fig. 2B).
tion at or near control levels. Without treatment, BPK
cystic mice (N 5 10) have BUN levels 10 times that ofSurvival studies
unaffected littermates (N 5 20) at the time of their deathEKI-785 treatment was extended past day 24 in 16
(P , 0.01). There is also a threefold decrease in theaffected animals and in 44 unaffected mice. All unaf-
maximal urinary concentrating ability of affected micefected mice survived the treatment until day 48. Thirteen
(P , 0.01). Cystic BPK mice treated with EKI-785 fromof the 16 treated affected animals survived to day 48,
P-7 to P-24 (N 5 14) have serum BUN and creatinineand 9 affected animals were sacrificed at this time point.
levels significantly below untreated BPK cystic animalsAffected animals treated with EKI-785 had a life span
(P , 0.01) as well as significantly increased maximumof greater than 46 6 4 days (9 healthy affected animals
urinary concentrating ability (P , 0.01). Cystic animalssacrificed at P-48) compared with an average time to
treated to P-48 (N 5 9) show a slight increase in the CTdeath of 23.5 6 3 in untreated affected mice. The CT
cystic index; however, serum BUN and creatinine lev-cystic index of animals treated with EKI-785 to P-48 was
els are essentially unchanged compared with P-24–60% less than the CT cystic index of P-24 untreated
untreated controls (N 5 10) or P-48–treated controlsaffected animals (P , 0.02). Figure 2E demonstrates a
(N 5 16). The maximum urinary concentrating ability ofdramatic reduction in CT cystic lesions in P-48–treated
P-48–treated cystic mice is, however, significantly highercystic kidneys compared with P-24–untreated cystic kid-
(1003 6 54 mOsm/L) than P-24–untreated cystic animalsneys (Fig. 2A).
(361 6 74, P , 0.01). Cystic animals treated to P-48EKI-785 treatment also altered the cyst localization
profile of BPK mice. In BPK cystic mice [14], as in other demonstrated no statistically significant differences of
b
Fig. 2. Representative morphology of (A) postnatal day 24 (P-24)–untreated kidney from cystic BPK animal. Brown staining represents lectin
identified CT. (B) P-24–untreated liver from cystic BPK animal (C). P-24 EKI-785–treated kidney from cystic BPK animal. Brown staining
represents lectin identified CT. (D) P-24 EKI-785–treated liver from cystic BPK animal. (E) P-48 EKI-785–treated kidney from cystic BPK animal.
Brown staining represents lectin identified CT. (F) P-48 EKI-785–treated liver from cystic BPK animal. (G) P-48 EKI-treated kidney from unaffected
animal. Brown staining represents lectin identified CT, and (H) P-48 EKI-treated liver from unaffected animal. Data demonstrate that EKI-785
treatment results in a dramatic reduction in size and number of CT cystic lesions (C and E) vs. untreated kidney (A), as well as reduced biliary
ectasia (D and F) vs. untreated liver (B) without morphological evidence of kidney (G) or liver (H) toxicity (hematoxylin, original magnification
of A, C, E, G 325; original magnification of B, D, F, H 366).
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Table 1. Renal function, cystic index and biliary proliferation, and ductule ectasia (BDE) with and without EKI-785 treatment
BUN Creatinine Urine osmolarity
mg/dl mOsm/L Cystic index BDE
Con (P-24) 19 62 0.260.1 1134652 0 0
CY (P-24) 191 631a 0.660.2a 361674a 4.860.4a 3.260.6a
Con 1 EKI (P24) 1862 0.260.1 1182637 0 0
CY 1 EKI (P24) 19 64b 0.260.1b 1099647b 1.660.5b 1.260.4c
Con 1 EKI (P48) 1563 0.260.1 1176655 0 0
CY 1 EKI (P48) 20 63d 0.360.1d 1003654d 2.060.5e 2.060.5e
The number of samples analyzed in each group is as follows: Con (P-24), N 5 20; CY (P-24), N 5 10; Con 1 EKI (P-24), N 5 14; CY 1 EKI (P-24), N 5 14;
Con 1 EKI (P-48), N 5 16; Cy 1 EKI (P-48), N 5 9. Con (P-24) vs. CY 1 EKI (P-24) and Con (P-24) 1 EKI vs. CY 1 EKI (P-24) are NS.
a Con (P-24) vs. CY (P-24), P , 0.01
b CY (P-24) vs. CY 1 EKI (P-24), P , 0.01
c CY (P-24) vs. CY 1 EKI (P-24), P , 0.02
d CY (P-24) vs. CY 1 EKI (P-48), P , 0.01
e CY (P-24) vs. CY 1 EKI (P-48), P , 0.02
treated with EKI-785 to P-24 (N 5 19) or P-48 (N 5 16)
is statistically the same as untreated, unaffected controls.
Pilot toxicology studies on other organs demonstrated no
compound-related deaths and no microscopic changes in
heart, spleen, stomach, or thymus.
DISCUSSION
Extensive morphological analysis and mathematical
modeling of cyst formation and growth have indicated
that epithelial hyperplasia is a necessary element in the
formation and growth of cystic lesions in PKD [33]. De-
spite some conflicting reports [34–36], a significant role
for the EGF/TGF-a/EGFR axis in mediating hyperplas-
tic expansion of renal tubular epithelium has been estab-
Fig. 3. Response following withdrawal of EKI-785. Symbols are: (s) lished in both ADPKD and ARPKD [reviewed in 7].
untreated; (e) EKI-785; (∗) withdrawn. Four animals were treated with These data support the potential therapeutic value ofEKI-785 (90 mg/kg) every three days starting at P-7 and continuing to
EGFR tyrosine kinase inhibition in decreasing CT cystP-46 (14 total doses). At P-48, the drug was withdrawn, and progression
of cystic lesions was followed. Data demonstrate that EKI-785 (90 mg/ formation and growth. Such studies demonstrate that:
kg) is effective in slowing the progression and growth of CT cysts during (a) EGF and TGF-a are cystogenic in a variety of inthe entire treatment period. However, withdrawal of EKI-785 results in
vitro systems [15, 17, 22]; (b) cyst fluid from ADPKD,immediate CT cyst progression and growth similar in slope to untreated
kidneys. ARPKD, rat and murine models of PKD contain immu-
noreactive EGF-like peptides in mitogenic quantities
[11, 12]; (c) cystic kidneys have increased TGF-a mRNA
levels [37]; (d) overexpression of TGF-a in transgenicmaximum urinary concentrating ability when compared
mice causes renal cystic abnormalities [10]; (e) EGFR iswith untreated (N 5 10) or treated controls (N 5 16).
overexpressed and mislocalized to the apical membrane
Toxicology of cystic epithelia in human ADPKD, human ARPKD,
and murine models of ARPKD and ADPKD [8, 9, 13,Figure 2G (EKI-785–treated kidney) and Figure 2H
16, 19–21]; ( f) abnormally expressed apical EGFRs in(EKI-785–treated liver), which are indistinguishable
PKD are capable of high-affinity EGF binding and auto-from untreated control kidney and liver, demonstrate
phosphorylation and can initiate a signaling cascade thatthat EKI-785 treatment at 90 mg/kg every three days
results in increased mitotic activity [19]; and (g) EGFRproduces no morphologic evidence of toxicity in kidney
TKIs decrease EGF-driven cyst progression in meta-or liver. The lack of kidney toxicity at 90 mg/kg every
nephric organ culture [17, 22].three days is supported by the fact that serum BUN
In this study, a newly developed EGFR TKI (EKI-and creatinine levels as well as the maximum urinary
785) was tested in the BPK murine model of ARPKD.concentrating ability of P-24 and P-48 EKI-785–treated
Specific outcomes evaluated included (a) a reduction ofanimals is not significantly different from control values.
In addition, the urinary function of unaffected animals CT cyst formation and growth, (b) improvement in renal
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function, (c) reduction in biliary abnormalities, and (d) ORPK models) are on different chromosomes, and none
decreased mortality. EKI-785 is a new member of a class of these genes are syntenic with the human ARPKD or
of synthetic compounds designed to inhibit EGFR activ- ADPKD genes. Increased apical CT EGFR expression
ity by binding to the ATP binding site of EGFR [25]. demonstrated in both murine and human ARPKD and
EKI-785 inhibits (a) the catalytic activity of the purified ADPKD is thus a common cellular phenotype down-
EGFR kinase (IC50 5 420 pmol/L), (b) autophosphory- stream from a number of different primary gene defects
lation of EGFR (IC50 5 5 nmol/L), and (c) mitogenesis in PKD [9, 13, 16, 18, 19, 21, 24].
in a variety of cells that overexpress EGFR [25]. EKI- Increased EGFR expression in cystic CT lesions pro-
785 has also been shown to inhibit c-erbB-2 activity. In vides a direct target for therapeutic intervention. Al-
a recent study, we have demonstrated that EKI-785 can though IP injection creates systemic exposure to EKI-
reduce EGF-induced CT cyst progression in metanephric 785, the pharmacological properties of this drug, as well
organ culture [22]. as its concentration in urine, provide indirect means of
In this study, IP injection of EKI-785 was shown to targeting this compound to abnormal EGFR of renal CT
be effective in reducing the growth and expansion of CT [25]. During in vitro studies of EKI-785’s effectiveness to
cysts in BPK mice. Treatment of cystic animals with EKI- inhibit epithelial cell proliferation, it was found that the
785 minimized CT cystic growth and maintained renal concentration necessary to inhibit proliferation was 4- to
function near control values over the course of the treat- 12-fold lower in cells that overexpress EGFR [25]. This
ment regimen. Treatment of BPK animals with EKI-785 creates a potential therapeutic window through which
at 90 mg/kg every three days was effective in doubling the drug administration could target cells that overexpress
expected lifespan of affected animals. Sixteen affected EGFR (that is, cystic CT cells) while minimizing effects
animals were treated past the average age of death on normal epithelium. Such a strategy minimizes systemic
(P-23.5 6 3) of untreated affected animals. Thirteen exposure to EKI-785. In this study, doses of 90 mg/kg IP
treated animals survived to P-48 (point of sacrifice), with Q3D up to P-46 (14 doses) produced no toxicity.
a minimal increase in CT cystic index and normalization We have previously suggested that biliary epithelial
of serum BUN, serum creatinine, and maximal urine cells in affected BPK animals demonstrate abnormalities
osmolarity. EKI-785 treatment was also effective in re- of EGFR expression that are similar to those of renal CT
ducing the level of biliary ductule ectasia and biliary epithelium [13]. The decrease in biliary epithelial hyper-
epithelial proliferation seen in untreated cystic animals. plasia seen in EKI-785–treated animals supports these
This study did not address the maximal survival length data (Fig. 2 F, H, and Table 1) and may be relevant to
with prolonged EKI-785 treatment. However, the data human ARPKD where biliary epithelial proliferation and
demonstrate that treatment of cystic BPK mice with ectasia leads to significant morbidity and mortality [2].
EKI-785 significantly prolongs the lifespan and that This study demonstrates that EKI-785 is a potent non-
treatment withdrawal leads to immediate progression of toxic compound that has therapeutic effectiveness in a
PKD in this model. well-characterized animal model of ARPKD. Targeting
It is notable that in a recent study, the oral administra- the cystic EGFR cellular phenotype common to murine
tion of a nonspecific TKI, genistein, had no effect on cyst and human ARPKD and ADPKD with EKI-785, and
formation in the pcy murine PKD model. It is difficult to similar compounds may have value in the treatment of
evaluate this study critically in relationship to the current human PKD.
findings given the differences between the experimental
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